Evidence map›Paper›PMID 31757576›Full record

ArticleNeurobiology of aging2020

Modified ketogenic diet is associated with improved cerebrospinal fluid biomarker profile, cerebral perfusion, and cerebral ketone body uptake in older adults at risk for Alzheimer's disease: a pilot study.

Bryan J Neth, Akiva Mintz, Christopher Whitlow, Youngkyoo Jung, Kiran Solingapuram Sai, Thomas C Register, Derek Kellar, Samuel N Lockhart, Siobhan Hoscheidt, Joseph Maldjian and 6 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurobiology of aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06444568 (Efficacy of Modified Ketogenic Diet in Amnestic Mild Cognitive Impairments), which is not on this map. Cited by 125 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 7 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06444568 naunknown statusnot on this mapstarted 2024, after this paper: background citation

Efficacy of Modified Ketogenic Diet in Amnestic Mild Cognitive Impairments

TypeinterventionalSponsorSaglik Bilimleri UniversitesiRan2024 to 2025Enrolled36ConditionsAmnestic Mild Cognitive Disorder, Amnestic Mild Cognitive ImpairmentArmsDietary Intervention
3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 7 syntheses or guidelines pooled it, 199 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Trial
  9. Trial
  10. A ketogenic drink improves cognition in mild cognitive impairment: Results of a 6-month RCT.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021
    Trial
  11. The Biochemical Role of Bitter Melon (Food science & nutrition · 2026
    Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 4 countries.

Bryan J NethDepartment of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Akiva MintzDepartment of Radiology, Wake Forest School of Medicine, Winston-Salem, NC, USA; Department of Radiology, Columbia University, New York, NY, USA.
Christopher WhitlowDepartment of Radiology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Youngkyoo JungDepartment of Radiology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Kiran Solingapuram SaiDepartment of Radiology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Thomas C RegisterDepartment of Pathology - Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Derek KellarDepartment of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Samuel N LockhartDepartment of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Siobhan HoscheidtDepartment of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Joseph MaldjianDepartment of Radiology, Wake Forest School of Medicine, Winston-Salem, NC, USA; Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Amanda J HeslegraveDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK; UK Dementia Research Institute at UCL, London, UK.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Stephen C CunnaneResearch Centre on Aging, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
Christian-Alexandre CastellanoResearch Centre on Aging, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
Henrik ZetterbergDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK; UK Dementia Research Institute at UCL, London, UK; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Suzanne CraftDepartment of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: suzcraft@wakehealth.edu.
Wake Forest University · USUniversité de Sherbrooke · CAColumbia University · USNational Hospital for Neurology and Neurosurgery · GBSahlgrenska University Hospital · SEThe University of Texas Southwestern Medical Center · USUniversity of Gothenburg · SE

Funding

Wake Forest Alzheimer's Disease Core CenterP30AG049638 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ESPELAND, MARK ANDREW · 2016 to 2020
$12.2M
NIA NIH HHS P30 AG049638
6 · The paper itself

Abstract

There is currently no established therapy to treat or prevent Alzheimer's disease. The ketogenic diet supplies an alternative cerebral metabolic fuel, with potential neuroprotective effects. Our goal was to compare the effects of a modified Mediterranean-ketogenic diet (MMKD) and an American Heart Association Diet (AHAD) on cerebrospinal fluid Alzheimer's biomarkers, neuroimaging measures, peripheral metabolism, and cognition in older adults at risk for Alzheimer's. Twenty participants with subjective memory complaints (n = 11) or mild cognitive impairment (n = 9) completed both diets, with 3 participants discontinuing early. Mean compliance rates were 90% for MMKD and 95% for AHAD. All participants had improved metabolic indices following MMKD. MMKD was associated with increased cerebrospinal fluid Aβ42 and decreased tau. There was increased cerebral perfusion and increased cerebral ketone body uptake (

Indexed as

Diet, MediterraneanAgedAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersCerebrovascular CirculationCross-Over StudiesFemaleHumansKetone BodiesMaleMemoryMiddle AgedPeptide FragmentsPilot ProjectsRiskAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersKetone BodiesPeptide FragmentsAlzheimer's diseaseCSF biomarkersKetogenic dietMild cognitive impairmentMRIPET

Identifiers

PMID31757576
PMCPMC7266642
OpenAlexW2975582353

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.